Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes

CONCLUSIONS: Ticagrelor and prasugrel are increasingly used in patients with CCS undergoing PCI with similar 1-year efficacy and safety when compared to clopidogrel. Whether use of these agents can be beneficial in patients undergoing PCI for CCS with a high thrombotic and low bleeding risk warrants further study.PMID:36660810 | DOI:10.4244/EIJ-D-22-00654

Source: EuroIntervention - January 20, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Anoop N Koshy Gennaro Giustino Samantha Sartori Amit Hooda Yihan Feng Clayton Snyder Shabitri Dasgupta Kartik R Kumar Parasuram Krishnamoorthy-Melarcode Joseph Sweeny Sahil Khera Gregory W Serrao Raman Sharma George Dangas Annapoorna S Kini Roxana Mehran Source Type: research